Humulin Insulin Mixtard — Competitive Intelligence Brief

Humulin Insulin Mixtard (Humulin Insulin Mixtard) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin combination (rapid-acting + intermediate-acting). Area: Diabetes.

phase 3 Insulin combination (rapid-acting + intermediate-acting) Insulin receptor Diabetes Small molecule

Target snapshot

Humulin Insulin Mixtard (Humulin Insulin Mixtard) — Ain Shams University. Humulin Insulin Mixtard is a fixed combination of rapid-acting and intermediate-acting insulin that replaces or supplements endogenous insulin to regulate blood glucose levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Humulin Insulin Mixtard TARGET	Humulin Insulin Mixtard	Ain Shams University	phase 3	Insulin combination (rapid-acting + intermediate-acting)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin combination (rapid-acting + intermediate-acting) class)

1. Ain Shams University · 1 drug in this class
2. Eli Lilly and Company · 1 drug in this class